{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:53:02Z","timestamp":1766087582434,"version":"3.45.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.eclinm.2020.100410","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T16:35:24Z","timestamp":1593621324000},"page":"100410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Subcutaneous tocilizumab treatment in patients with severe COVID-19\u2013related cytokine release syndrome: An observational cohort study"],"prefix":"10.1016","volume":"24","author":[{"given":"Antonio","family":"Mastroianni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Apuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Oriolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Zanolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Chidichimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Vangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2020.100410_bib0001","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2020.100410_bib0002","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2020.100410_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/CM9.0000000000000722","article-title":"Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study","volume":"133","author":"Ren","year":"2020","journal-title":"Chin Med J"},{"key":"10.1016\/j.eclinm.2020.100410_bib0004","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019. Accessed May 6, 2020.","key":"10.1016\/j.eclinm.2020.100410_bib0005"},{"key":"10.1016\/j.eclinm.2020.100410_bib0006","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2020.100410_bib0007","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.eclinm.2020.100410_bib0008","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression [letter]","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2020.100410_bib0009","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients [letter]","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.eclinm.2020.100410_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2020.100410_bib0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.eclinm.2020.100410_bib0012","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2020.100410_bib0013","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eclinm.2020.100410_bib0014","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2020.100410_bib0015","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2020.100410_bib0016","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.eclinm.2020.100410_bib0017","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2020.100410_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40744-018-0102-x","article-title":"A review of recent advances using tocilizumab in the treatment of rheumatic diseases","volume":"5","author":"Rubbert-Roth","year":"2018","journal-title":"Rheumatol Ther"},{"doi-asserted-by":"crossref","unstructured":"Zhou Y., Fu B., Zheng X., et\u00a0al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus [preprint]. https:\/\/www.biorxiv.org\/content\/10.1101\/2020.02.12. 945576v1. Accessed May 6, 2020.","key":"10.1016\/j.eclinm.2020.100410_bib0019","DOI":"10.1101\/2020.02.12.945576"},{"key":"10.1016\/j.eclinm.2020.100410_bib0020","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.eclinm.2020.100410_bib0021","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ajh.25833","article-title":"Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab","volume":"95","author":"De Luna","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eclinm.2020.100410_bib0022","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diii.2020.03.010","article-title":"Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab [comment]","volume":"101","author":"Cellina","year":"2020","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.eclinm.2020.100410_bib0023","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.eclinm.2020.100410_bib0024","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2020.100410_bib0025","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"unstructured":"Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49409. Accessed May 6, 2020.","key":"10.1016\/j.eclinm.2020.100410_bib0026"},{"unstructured":"Clinical Trials Arena. Roche to start phase III trial of Actemra in Covid-19 patients [press release]. March 19, 2020. https:\/\/www.clinicaltrialsarena.com\/news\/roche-actemra-covid-19-trial\/. Accessed 6 May 2020.","key":"10.1016\/j.eclinm.2020.100410_bib0027"},{"key":"10.1016\/j.eclinm.2020.100410_bib0028","article-title":"Calculated decisions: brescia-COVID respiratory severity scale (BCRSS)\/algorithm","volume":"22","author":"Duca","year":"2020","journal-title":"Emerg Med Pract"},{"key":"10.1016\/j.eclinm.2020.100410_bib0029","doi-asserted-by":"crossref","DOI":"10.1148\/ryct.2020200047","article-title":"Chest CT severity score: an imaging tool for assessing severe COVID-19","author":"Yang","year":"2020","journal-title":"Radiol Cardiothoracic Imaging"},{"key":"10.1016\/j.eclinm.2020.100410_bib0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jcph.185","article-title":"Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)","volume":"54","author":"Ohta","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eclinm.2020.100410_bib0031","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","article-title":"Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)","volume":"75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eclinm.2020.100410_bib0032","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.eclinm.2020.100410_bib0033","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/eci.12799","article-title":"Effects of tocilizumab on neutrophil function and kinetics","volume":"47","author":"Lok","year":"2017","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.eclinm.2020.100410_bib0034","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","volume":"77","author":"Lauper","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eclinm.2020.100410_bib0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5414\/CP201819","article-title":"Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects","volume":"51","author":"Zhang","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100410_bib0036","doi-asserted-by":"crossref","first-page":"620","DOI":"10.5414\/CP201904","article-title":"Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis","volume":"51","author":"Zhang","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2020.100410_bib0037","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eclinm.2020.100410_bib0038","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1007\/s00330-020-06731-x","article-title":"Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China","volume":"30","author":"Pan","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eclinm.2020.100410_bib0039","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020301541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020301541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:02:07Z","timestamp":1762887727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537020301541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":39,"alternative-id":["S2589537020301541"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100410","relation":{},"ISSN":["2589-5370"],"issn-type":[{"type":"print","value":"2589-5370"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous tocilizumab treatment in patients with severe COVID-19\u2013related cytokine release syndrome: An observational cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100410"}}